Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2026 Nov 13.
Published in final edited form as: Cancer Lett. 2026 Oct 26;662:218927. doi: 10.1016/j.canlet.2026.218927

MUC16 drives macrophage-mediated immunosuppression in pancreatic cancer

Christabelle Rajesh 1, Satish Sagar 1, Ying Huang 1, Clara S Mundry 1, Vijender Chaitankar 1, Osama Shiraz Shah 1, Charitha Sumeet 1, Thomas Caffrey 1, Kelly A O’Connell 1, Benjamin Swanson 2, Fang Yu 3, Richard R Behringer 4, Abeesh Prathapan 5,6, Michael A Hollingsworth 1, Prakash Radhakrishnan 5,6,*
PMCID: PMC13756213  NIHMSID: NIHMS2221146  PMID: 42933591

Abstract

Mucin-16 (MUC16) is overexpressed in >60% of pancreatic ductal adenocarcinoma (PDAC) cases and correlates with poor outcomes, yet its role in regulating tumor-immune interactions remains incompletely defined. Using KPC and KPC-MUC16 knockout (KPC-MUC16KO) genetically engineered and orthotopic mouse models, we show that loss of MUC16 markedly reduces tumor burden and reprograms the tumor microenvironment (TME) toward a less immunosuppressive state. MUC16 deficiency significantly decreased CD206+ and Ym1/2+ M2-like macrophages, increased the M1/M2 ratio, and improved survival. Cytokine profiling identified CCL2 and Serpin-E1 as MUC16-dependent secreted factors that promote macrophage recruitment and polarization; neutralization of these cytokines reduced macrophage migration in vitro. Bone marrow-derived macrophages (BMDM) exposed to MUC16-expressing tumor cells or conditioned media adopted a CD206+Arg1+ M2-like phenotype, whereas MUC16KO tumor signals favored inflammatory CD86+iNOS+ M1-like polarization. Macrophage depletion using clodronate liposomes significantly impaired tumor growth in MUC16-competent tumors but had minimal effect in KPC-MUC16KO tumors, indicating dependence on macrophage-mediated immunosuppression in the former group. Spatial transcriptomics revealed a globally distinct TME in MUC16KO tumors, including enhanced antigen-presentation programs, increased complement activation, and fibroblast states skewed toward pro-inflammatory signaling. These findings establish MUC16 as a key orchestrator of macrophage-driven immunosuppression in PDAC and support therapeutic strategies combining MUC16-targeted interventions with TME-reprogramming approaches.

Keywords: pancreatic cancer, immunosuppression, macrophages, MUC16, tumor microenvironment

Introduction

Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic cancer incidence and is an extremely lethal malignancy [1]. The overall 5-year survival rate remains a dismal 13% [2], largely due to late-stage diagnosis, with more than half of patients presenting with distant metastases at the time of detection. In such cases, surgical resection, the only curative strategy is no longer feasible. Current standard-of-care (SoC) therapies, including FOLFIRINOX, NALIRIFOX or gemcitabine combined with nab-paclitaxel, offer limited survival benefit [3,4]. Recently, KRAS inhibition with daraxonrasib, a RAS(ON) inhibitor, has shown the longest overall survival (OS) to date in previously treated metastatic PDAC (13.2 months vs 6.7 months on SoC) in a randomized clinical trial [5]. Daraxonrasib has since been approved to treat metastatic PDAC in patients who have received at least one prior therapy, and is the first Ras-targeted agent to reach this milestone in PDAC [6].

PDAC tumors are characterized by poorly differentiated tumor epithelium, particularly at advanced stages, as well as a highly dysplastic and fibrotic stroma [7]. Driver mutations in KRAS and TP53 are hallmarks of this cancer. Notably, mutant KRAS has been shown to upregulate the expression of Mucin-16 (MUC16), a heavily glycosylated protein overexpressed in more than 65% of PDAC cases and absent in the normal pancreas, thereby providing a therapeutic window for tumor targeting [8,9]. High MUC16 expression correlates with poor prognosis and reduced overall survival and has been implicated in promoting tumor cell-autonomous signaling in PDAC [9]. However, its impact on the tumor microenvironment (TME) remains insufficiently explored. The TME plays a central role in PDAC progression. PDAC exhibits a dense, stromal-rich microenvironment populated by tumor-supportive cell types, including macrophages. These immune cells are often reprogrammed into non-cytotoxic, tumor-promoting phenotypes, contributing to the “immunologically cold” nature of PDAC, which lacks effective anti-tumor immune responses [10,11].

Emerging literature indicates that MUC16 contributes to immunosuppression in the tumor microenvironment, implicating it in cancer progression beyond its role as a clinical biomarker in patients with ovarian cancer [12-14]. More specifically, MUC16 mediates this by impairing natural killer (NK) cell-mediated cytotoxicity [15]. Its extensive N- and O-glycosylation is critical for these functions. In ovarian cancer, specific alpha-2,3 and alpha-2,6 sialic acid linkages on MUC16 bind the immunosuppressive receptor Siglec-9 on NK cells, monocytes, and B cells, thereby dampening anti-tumor immunity [16]. These findings suggest that MUC16 might have broader immunomodulatory roles across tumor types and supports the model of immunomodulatory scaffolding functions of tumor-associated carbohydrate antigens, including MUC16, by engaging with or facilitating signaling through immune-inhibitory receptors to suppress anti-tumor immunity.

Macrophages represent a dominant immune population in human PDAC and are well-established mediators of tumor progression [17]. These immunosuppressive macrophages, commonly referred to as tumor-associated macrophages (TAMs), arise from both circulating monocytes recruited into the tumor and resident macrophages within the pancreas [7,18,19]. TAMs drive multiple tumor-promoting processes, including T cell exhaustion, aberrant angiogenesis, invasion, metastasis, and immune evasion [20-23]. Based on these compelling findings, it is important to delineate tumor-cell-intrinsic mechanisms that influence macrophage recruitment and polarization within the TME, ultimately positioning tumor-supportive macrophages as key arbiters of pancreatic cancer.

Loss of MUC16 profoundly reshapes macrophage-associated immune states within the PDAC tumor microenvironment. Using immunocompetent KPC and KPC-MUC16KO mouse models, we demonstrate that MUC16 deletion not only markedly reduces tumor burden but also drives a striking shift in macrophage populations within the TME. Spatial transcriptomic profiling and immunostaining reveal that loss of MUC16 reconfigures tumor composition and establishes a distinct tumor–immune architecture characterized by inflammatory and antigen-presentation programs in macrophages, including enhanced ligand–receptor interactions involving MHC class II molecules. Although macrophage depletion with clodronate liposomes in MUC16-expressing KPC tumors significantly reduces tumor burden, it fails to elicit T-cell immunity highlighting that macrophage reprogramming, as observed in MUC16KO tumors, may be more effective than broad macrophage ablation.

Collectively, these findings identify MUC16 as a tumor cell-autonomous regulator of macrophage-mediated immunosuppression in the PDAC microenvironment. This work underscores MUC16 as a targetable axis for restoring anti-tumor immunity in a disease defined by profound immune evasion.

Results

MUC16 alters tumor progression and macrophage status in PDAC

To understand the role of MUC16 in tumor progression, we utilized a genetically engineered mouse model of MUC16-competent PDAC and generated a corresponding MUC16-knockout (KO) model by crossing KPC mice (KrasLSLG12D/+; p53R172H/+; Pdx-CreTg/+) with MUC16-null mice (exon 3 deletion). MUC16-null animals do not display any prominent abnormal phenotype in the pancreas and other organs (ovary, lung, uterus, testis) up to 1 year of age [24-26]. These immunocompetent KPC and KPC-MUC16KO models in a C57BL/6 background exhibit markedly different tumor progression at 4 months (Figure 1A). Both models retain expression of epithelial cytokeratin-19 and the ductal maintenance marker SOX-9, indicative of acinar-to-ductal metaplasia (ADM) characteristic of PDAC (Figure 1A) [27]. Histological analyses show that, relative to age-matched (4-month-old) KPC mice, tumors from KPC-MUC16KO mice progress slowly and display larger areas of normal acinar tissue, early pancreatic intraepithelial neoplasms (PanINs), and reduced full-blown PDAC (Figure 1B).

Figure 1: MUC16 affects the TME and tumor burden.

Figure 1:

KPC and KPC-MUC16KO genetically engineered mouse models show tumor formation at 4-months of age. A. Images depict (H&E), and immunostaining for MUC16 (red), Cytokeratin-19 and SOX-9; B. Histological analysis and scoring of normal, ADM, PanINs and PDAC in KPC and KPC-MUC16KO models; C. Ingenuity Pathway Analysis of RNA sequencing from KPC and KPC-MUC16KO cell lines showing inhibition of myeloid recruitment and phagocytes in KPC-MUC16KO cells; D. Immunostaining for F4/80, CD86 and CD206 in KPC (n=8) and KPC-MUC16KO (n=3) tissues, and representative histoscore graphs and M1/M2 ratio; E. Tumor images upon euthanasia at day 24 post implantation in an orthotopic model; Tumor F. weight and G. volume; H. Immunostaining for F4/80, CD86 and CD206 in KPC (n=5) and KPC-MUC16KO (n=5) orthotopic tumor tissues, and representative histoscore graphs and M1/M2 ratio; I. Survival study for orthotopic KPC (n=8) and KPC-MUC16KO (n=11) tumors in C57BL/6 mice. p values < 0.05 considered statistically significant.

RNA sequencing followed by Ingenuity Pathway Analysis of differentially expressed genes using KPC and KPC-MUC16KO tumor-derived cell lines revealed significant inhibition of phagocyte and myeloid cell recruitment pathways in the KPC-MUC16KO model, driven in part by reduced CSF2 (GM-CSF) expression (Figure 1C). GM-CSF is known to recruit and polarize macrophages, and prior studies demonstrate that myeloid cells particularly macrophages are strongly influenced by tumor-promoting glycans and constitute a major immune population within the PDAC TME, including roles in ADM [20,22,23,28]. These findings led us to investigate macrophage infiltration in our differentially expressing models of MUC16.

In these GEMMs, total F4/80+ macrophage infiltration was comparable between KPC and KPC-MUC16KO tumors, and a similar trend was observed with CD86+ M1-like inflammatory macrophages. However, CD206+ tumor-promoting M2-like macrophages were significantly reduced in KPC-MUC16KO tumors (Figure 1D). A high M1/M2 ratio is associated with better prognosis [29], and consistent with this, the M1/M2 ratio was significantly elevated (p=0.0257) in KPC-MUC16KO tumors (Figure 1D), aligning with their reduced tumor progression.

To validate these observations independently of whole-body MUC16 loss, we used an orthotopic model. KPC and KPC-MUC16KO cells were implanted into the pancreas. After 24 days, mice were euthanized and tumors assessed. KPC-MUC16KO tumors exhibited significantly lower tumor burden, measured by weight (p<0.0001) and volume (p=0.0007) (Figure 1E-G). Total F4/80+ macrophage presence remained similar between groups, but CD86+ M1-like macrophages were increased in MUC16KO tumors (p=0.0140), and M2-like Ym1/2+ macrophages showed a slight, though not statistically significant, reduction (Figure 1H). As in the GEMMs, the M1/M2 ratio was significantly higher in the KPC-MUC16KO model (p=0.0077) (Figure 1H).

Given the established literature on MUC16-mediated oncogenic signaling and our findings on macrophage regulation, we conducted a survival study in immunocompetent C57BL/6 mice using the same orthotopic approach. Mice bearing KPC-MUC16KO tumors exhibited significantly prolonged survival (median 59 days) compared to the KPC tumor-bearing mice (median 35 days, p<0.0001) (Figure 1I). Collectively, these results indicate that loss of MUC16 substantially reduces tumor burden and robustly reshapes macrophage programming within the PDAC TME.

CCL2 and Serpin-E1 are regulators of MUC16-mediated macrophage programs

To identify regulators of MUC16-mediated effects on macrophages in PDAC, we performed an unbiased cytokine screen, given their central role in immune modulation in cancer. Isogenic PDAC T3M4 and T3M4-MUC16KO cells were used to generate tumor-conditioned media, as the parent cells express MUC16 and have previously been shown to promote tumor formation. We also chose the T3M4 model for this cytokine screen because cytokine-receptor signaling and secretome dynamics differ between mice and humans [30], and we aimed to identify hits in a more clinically relevant human model. Among the significantly downregulated cytokines, Serpin-E1 emerged as a notable regulator of macrophages, as previous reports highlight its role in promoting macrophage recruitment and tumor-associated macrophage (TAM) development (Figure 2A) [31]. We also evaluated CCL2 (monocyte chemoattractant protein-1, MCP-1) based on its well-established role in modulating myeloid cell recruitment in cancer [32-35].

Figure 2: MUC16 modulates cytokines to affect macrophage recruitment.

Figure 2:

A. Cytokine profile from tumor-conditioned media from T3M4 and T3M4-MUC16KO cell lines; ELISA for CCL2 in tumor-conditioned media from B. T3M4 and T3M4-MUC16KO and C. Capan-1 and Capan 1-MUC16KO cells; RT-PCR for CCL2 and Serpin-E1 gene expression in D. KPC and KPC-MUC16KO, E. T3M4 and T3M4-MUC16KO, F. Capan-1 and Capan 1-MUC16KO cells; Western blotting for p-AKT, total AKT, p-IKKα/β, IKKα, Serpin-E1, CCL2. GAPDH is used as a loading control in G. KPC and KPC-MUC16KO and H. T3M4, T3M4-MUC16KO, Capan-1 and Capan 1-MUC16KO cells; Immunostaining for Serpin-E1 and representative histoscore graph, immunostaining for CCL2 and representative mean fluorescence intensity graph in I. GEMM and J. Orthotopic KPC and KPC-MUC16KO mouse models; K. Chemotaxis of BMDMs towards control media (without cells) and KPC and KPC-MUC16KO cells (n=5); L. Chemotaxis of BMDMs towards control media (without cells) (n=4), tumor-conditioned media from KPC and KPC-MUC16KO cells, KPC conditioned media with CCL2, Serpin-E1 neutralization and dual neutralization (n=5). * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001, **** p ≤ 0.0001

ELISA analysis conditioned media from T3M4 and Capan-1 cells and their CRISPR-engineered MUC16 knockouts showed significantly reduced CCL2 secretion in MUC16KO cells (Figure 2B and 2C). Loss of MUC16 in mouse KPC, and human T3M4, and Capan-1 cells also led to significant downregulation of CCL2 but not Serpin-E1 gene expression (Figure 2D-F), suggesting transcriptional control of CCL2 specifically in MUC16-competent cells. Activation of AKT signaling (via p-AKT at S473) can induce the NF-kB pathway, by phosphorylated IKK-α/β, leading to increased CCL2 gene expression, as NF-kB directly binds to the CCL2 promoter [36,37]. In our cell line models, we observed decreased protein levels of p-AKT (S473), p-IKK-α/β, and total CCL2, consistent with this non-canonical AKT-dependent regulatory mechanism in MUC16-expressing cells (Figure 2G-H). Serpin-E1 protein levels were also reduced in MUC16KO cells consistent with its absence in conditioned media from these cells (Figure 2G-H).

Expression of both CCL2 and Serpin-E1 was significantly lower in KPC-MUC16KO tumors in both GEMM (Figure 2I) and orthotopic (Figure 2J) tumor models, reinforcing initial cytokine array findings. To assess functional relevance, we performed a Transwell chemotaxis assay. Bone marrow-derived macrophages (BMDMs) migrated more robustly toward KPC cells than toward KPC-MUC16KO cells (Figure 2K). Similarly, THP-1-derived human macrophages migrated significantly faster toward T3M4 cells than toward their MUC16KO counterparts (Supplemental Figure 1B).

Using conditioned media instead of cells, BMDM migration was greatest toward KPC-conditioned media and significantly reduced toward MUC16KO-conditioned media. Neutralizing antibodies against CCL2, Serpin-E1 or both decreased BMDM migration (Figure 2L), indicating that MUC16-dependent secretion of these cytokines actively contributes to macrophage recruitment in vitro, serving as a proxy for in vivo macrophage trafficking in KPC versus KPC-MUC16KO tumors.

Notably, dual neutralization was not more effective than blocking either cytokine alone. Moreover, none of the neutralization strategies reduced BMDM migration to the low levels observed with MUC16KO-conditioned media. This suggests that although CCL2 and Serpin-E1 are key contributors to macrophage recruitment, additional MUC16-regulated secreted factors likely participate, and the current study is not exhaustive in identifying these additional mediators.

MUC16 potentiates macrophage polarization to tumor-associated macrophages of the M2-like subtype

Both the GEMM and orthotopic tumor models show that KPC-MUC16KO tumors have a high M1/M2 ratio, an indicator of better prognosis, and this correlates with the reduced tumor burden observed in these models (Figure 1). To assess the specific influence of MUC16+ versus MUC16− tumor cells on macrophage polarization toward M1-like (anti-tumor, inflammatory) or M2-like (pro-tumor, anti-inflammatory, and reparative) states, we used an in vitro BMDM model system. Bone marrow cells isolated from normal (non-tumor-bearing) C57BL/6 mice differentiated to BMDMs using macrophage differentiation media containing M-CSF for 5 days, at which point >90% cells expressed the macrophage marker F4/80 (Figure 3A, Supplemental Figure 2A). BMDMs were then cocultured with tumor cells at two ratios as depicted in Figure 3A, for 48 hours before flow cytometric analysis. Gating on live, F4/80+ cells showed a higher proportion of macrophages in coculture with KPC cells compared with KPC-MUC16KO cells at both ratios (Supplemental Figure 2B). Among these F4/80+ macrophages, M1-like cells (CD86+iNOS+) were significantly increased in BMDMs cocultured with KPC-MUC16KO cells (p<0.0001, Figure 3B), whereas M2-like macrophages (CD206+Arg1+) were significantly reduced at both coculture ratios (p<0.0001, Figure 3C). These findings reinforce the role of MUC16 in skewing macrophage polarization toward immunosuppressive, tumor-supportive phenotypes. In a separate experiment, BMDMs were treated with control or tumor-conditioned media for 48 hours (Figure 3D). F4/80+ BMDMs (Supplemental Figure 2C) exposed to KPC-MUC16KO-conditioned media showed elevated CD86+iNOS+ expression and significantly reduced CD206+Arg1+ expression, when compared with both control and KPC-conditioned media treatments (p<0.0001, Figure 3E-F). These results mirror the effects observed in the coculture system. Additionally, conditioned media-treated BMDMs were also subjected to gene expression studies for an M2-like marker panel using real-time PCR. BMDMs exposed to MUC16-expressing KPC cells exhibited significantly higher expression of Arginase-1, IL-10, CXCL13, CD274 (encoding PD-L1), CD206, and IL-1β compared with BMDMs treated with KPC-MUC16KO conditioned media (Figure 3G-L). Together, these in vitro findings corroborate results from both genetically engineered and orthotopic mouse models, demonstrating that the presence of MUC16 on tumor cells profoundly shapes the TME by promoting macrophage reprogramming to TAMs that support PDAC development and persistence.

Figure 3: Pancreatic tumor cells expressing MUC16 facilitate TAM programs.

Figure 3:

A. Experimental design for in vitro tumor cell and macrophage (BMDM) coculture; Flow cytometry quantification for B. iNOS+ CD86+ and C. CD206+ Arg-1+ macrophages in the KPC and KPC-MUC16KO coculture at two ratios (1:1 or 2:1, macrophage: cancer cell); D. Experimental design for in vitro tumor conditioned media (CM) treatment on and BMDMs; Flow cytometry quantification for E. iNOS+ CD86+ and F. CD206+ Arg-1+ macrophages in control (media only), KPC and KPC-MUC16KO conditioned macrophages, RT-PCR on control (media only), KPC and KPC-MUC16KO conditioned macrophages for G. Arginase-1, H. IL-10, I. CXCL13, J. CD274, K. CD206, L. IL-1β expression. p values < 0.05 considered statistically significant.

Clodronate liposomes deplete splenic macrophages and drastically alter tumor burden and intratumor macrophage status

Clodronate liposomes are an effective method for depleting endogenous macrophages in vivo by facilitating macrophage “suicide” following phagocytic uptake of liposome-encapsulated clodronate [38]. Intravenous administration leads to macrophage depletion in the spleen, bone marrow and liver [39], and this strategy has been widely used to assess macrophage function across disease models, including cancer [40-43]. Based on our observations thus far, macrophage populations in KPC (MUC16-expressing) tumors differ markedly from those in KPC-MUC16KO tumors, and our in vitro data further validate the role of MUC16-competent tumor cells in recruiting and polarizing macrophages toward a tumor-supportive phenotype. To determine whether KPC and KPC-MUC16KO tumors differ in their dependence on macrophages, we employed clodronate liposomes administered intravenously 3 days before tumor implantation, followed by five additional doses to sustain macrophage depletion in tumor-bearing mice (Figure 4A). Neutral liposomes lacking clodronate served as controls. On day 21 post-implantation, spleens and pancreatic tumors were harvested for analysis. Clodronate liposomes-mediated macrophage depletion significantly reduced tumor burden in KPC (MUC16-expressing) tumors (Figure 4B), reflected by both tumor weight (Figure 4C) and volume (Figure 4D). As expected, control-treated KPC-MUC16KO tumors were significantly smaller than KPC tumors, and although clodronate-treated KPC-MUC16KO tumors showed the lowest tumor weight and volume overall, these values were not statistically different in control-treated KPC-MUC16KO tumors (Figure 4C-D). Histological evaluation by H&E staining revealed tumor architecture consistent with these observed differences in tumor burden (Figure 4E). The lack of response to clodronate in KPC-MUC16KO tumors suggests that these tumors recruit fewer macrophages initially and therefore do not rely on macrophage-driven support. In contrast, the substantial reduction in tumor burden in KPC tumors highlights their dependence on macrophages for tumor growth or maintenance.

Figure 4: Clodronate liposomes deplete macrophages and alter tumor burden.

Figure 4:

A. Experimental design for macrophage depletion using clodronate liposomes (and control neutral liposomes) in the orthotopic model. B. Tumor images upon euthanasia at day 21 post implantation for the following groups: KPC + control liposomes (n=5), KPC + clodronate liposomes (n=4), KPC-MUC16KO + control liposomes (n=7), KPC-MUC16KO + clodronate liposomes (n=6); Tumor C. Weight and D. Volume; E. H&E staining for tumor tissues from all groups (10x magnification); Staining and flow cytometry quantification for splenic macrophage populations – F. F4/80+ total macrophages, G. F4/80+ iNOS+ CD86+ M1-like macrophages, H. F4/80+ CD206+ M2-like macrophages, I. M1/M2 ratio, and intratumoral macrophage populations – J. F4/80+ total macrophages, K. F4/80+ iNOS+ CD86+ M1-like macrophages, L. F4/80+ CD206+ M2-like macrophages, M. M1/M2 ratio, in KPC + control liposomes, KPC + clodronate liposomes, KPC-MUC16KO + control liposomes, KPC-MUC16KO + clodronate liposomes tumor-bearing mice. p values < 0.05 considered statistically significant.

Flow cytometry of spleens and pancreas tumors from all four groups demonstrated that clodronate liposomes effectively depleted ~50% of splenic macrophages in both KPC and KPC-MUC16KO tumor-bearing mice (Figure 4F). This clodronate-liposome mediated reduction was accompanied by a significant increase in CD86+iNOS+ M1-like macrophages in KPC spleens (Figure 4G) and an almost complete loss of CD206+ M2-like macrophages in KPC-MUC16KO spleens (Figure 4H). Consequently, the M1/M2 ratio was significantly increased in the spleens of KPC-MUC16KO mice treated with clodronate liposomes compared to controls (Figure 4I). These findings suggest that changes in macrophages abundance and potentially macrophage-macrophage communication within the spleen of tumor-bearing mice influence their polarization state and functional characteristics.

In contrast to the spleen, intratumoral F4/80+ macrophages were not depleted in tumors from either KPC or KPC-MUC16KO groups (Figure 4J). This likely reflects the highly dysplastic, poorly vascularized nature of aggressive pancreatic tumors, which limits clodronate liposomes delivery particularly during later dosing when tumor interstitial pressure increases. Nonetheless, trends in M1- and M2-like macrophage populations were evident across groups. CD86+iNOS+ macrophages were highest and significantly elevated in clodronate-treated KPC-MUC16KO tumors (Figure 4K). CD206+ M2-like macrophages were lowest in clodronate-treated KPC-MUC16KO tumors, and control-treated KPC-MUC16KO tumors had significantly fewer CD206+ macrophages than control-treated KPC tumors (Figure 4L), consistent with immunostaining observations in Figure 1. The M1/M2 ratio increased with reduced tumor burden and was highest in clodronate-treated KPC-MUC16KO tumors (Figure 4M).

Splenic depletion of macrophages does not induce T cell responses

Activation of T cell responses against cancer is considered the gold standard for effective anti-tumor immunity, owing to the ability of CD8+ T cells to directly kill tumor cells upon recognizing tumor-associated antigens presented by MHC-I, and CD4+ T cells to facilitate immune recognition through MHC-II-mediated antigen-presentation by antigen-presenting cells (APCs) [44]. Spleens isolated from KPC and KPC-MUC16KO tumor-bearing mice treated with control or clodronate liposomes showed comparable levels of total CD3+ T cells (Figure 5A). A modest but significant reduction in CD4+ T cells was observed in KPC-MUC16KO spleens treated with control liposomes, with no additional CD4+ T cells differences noted across groups (Figure 5B). Unexpectedly, clodronate liposome treatment led to a reduction in cytotoxic CD8+ T cells in both KPC and KPC-MUC16KO spleens (Figure 5C). CD4+FOXP3+ regulatory T cells (Tregs) were reduced in clodronate-treated KPC spleens, while no other differences were observed for this population (Figure 5D). However, activated Tregs (CD4+FOXP3+CD25+) were significantly elevated in spleens from clodronate-treated KPC-MUC16KO tumor-bearing animals (Figure 5E), which, together with reduced cytotoxic T cells, suggests the emergence of a tumor-supportive T cell niche in clodronate liposome-treated mice.

Figure 5: Macrophage depletion alters splenic T cells.

Figure 5:

Staining and flow cytometry for splenic T cell populations – A. CD3+ total T cells, B. CD3+ CD4+ helper T cells, C. CD3+ CD8+ cytotoxic T cells, D. CD3+ CD4+ FOXP3+ regulatory T cells, E. CD3+ CD4+ FOXP3+ CD25+ activated regulatory T cells; and intratumoral T cell populations – F. CD3+ total T cells, G. CD3+ CD4+ helper T cells, H. CD3+ CD8+ cytotoxic T cells, I. CD3+ CD4+ FOXP3+ regulatory T cells, J. CD3+ CD4+ FOXP3+ CD25+ activated regulatory T cells in KPC + control liposomes, KPC + clodronate liposomes, KPC-MUC16KO + control liposomes, KPC-MUC16KO + clodronate liposomes tumor-bearing mice. p values < 0.05 considered statistically significant.

No significant differences were observed in intratumoral CD3+ total T cells, CD4+ helper T cells, CD8+ cytotoxic T cells, or T regs (Figure 5F-J). Over time, expansion of regulatory T cells can impair tumor regression and promote tumor progression by strengthening immunosuppressive conditions and reducing T cell activity. Although activated and regulatory T cell populations in tumors were unchanged between clodronate liposome- and control-treated mice, the increase in spleen-resident immunosuppressive T cells could still promote tumor growth through supporting immune evasion and potentially facilitating metastasis. Thus, despite the reduced tumor burden seen in clodronate-treated KPC-MUC16KO mice, long-term macrophage depletion may impair antigen presentation, as macrophages serve as one of three professional APCs, and ultimately permit tumor progression [45,46].

Circulating cytokine profiling showed that systemic inflammation was highest in KPC tumor-bearing mice treated with clodronate liposomes, followed by KPC-MUC16KO mice treated with clodronate liposome, compared with their respective controls and age-matched non-tumor bearing-mice (Supplemental Figure 3A). Additionally, KPC tumor-bearing mice treated with clodronate liposomes exhibited continuous body-weight decline beginning 12 days after orthotopic implantation (Supplemental Figure 3B), further suggesting that clodronate-mediated macrophage depletion is not a sustainable therapeutic strategy. Combined with the observed Treg activation, this approach may ultimately be counterproductive. Thus, rather than pursuing total macrophage depletion, reprogramming macrophages using CD40 agonists may offer a more effective and durable alternative (discussed later).

Spatial transcriptomics shows loss of MUC16 has immunomodulatory effects in a globally distinct TME

We leveraged Visium HD based spatial transcriptomics to characterize the global TME in the context of differential macrophage programs in orthotopic KPC and KPC-MUC16KO tumor models. UMAP clustering revealed the presence of macrophages, fibroblasts, dendritic cells, B cells, T cells and proliferating immune cells, in addition to epithelial and endothelial compartments (Figure 6A). Heatmap clustering identified top macrophage-associated genes, including Lyz2, Arg1, C1qa, C1qc, and H2-Aa (Supplemental Figure 4A). Overall epithelial cell proportions were not markedly different between groups, although one KPC tumor (sample 4690) exhibited increased global macrophage representation. KPC-MUC16KO tumors showed a higher proportion of fibroblasts compared to KPC tumors (Figure 6B). Spatial mapping of tumor and TME compartments revealed intense macrophage presence at the tumor periphery, and extending into the core of KPC tumors. In contrast, KPC-MUC16KO tumors showed macrophages concentrated at the periphery with sparser distribution throughout the tumor core, consistent with infiltrating macrophage populations (Figure 6C, Supplemental Figure 4B). Mapping Arginase-1 expression, a marker of tumor-promoting macrophages, demonstrated strong overlap with macrophage-dense regions in KPC tumors but minimal expression in KPC-MUC16KO tumors (Figure 6D, Supplemental Figure 4C), aligning with all of our aforementioned findings described herein.

Figure 6: Spatial transcriptomics points to immune activation in KPC-MUC16KO orthotopic tumors.

Figure 6:

A. UMAP clustering of cell types in orthotopic tumors from KPC (n=2) and KPC-MUC16KO (n=2). B. Population analysis depicting percentages of cell types in KPC and KPC-MUC16KO tumors. C. Spatial distribution of cell types including epithelial cells, dendritic cells, fibroblasts, endothelial cells, macrophages, proliferating immune cells and B cells in a KPC (sample 4690) and a KPC-MUC16KO (sample 4342) tumor. D. Arginase-1 spatial gene expression in a KPC (sample 4690) and a KPC-MUC16KO (sample 4342) tumor. Ligand-Receptor interaction modeling in KPC tumors (n=2) shown using a E. Heatmap depicting number of interactions between different cell types, F. Specific Ligand-Receptor pairs involved in macrophage-to-target cell crosstalk, G. Specific Ligand-Receptor pairs involved in source cell type-to-macrophage crosstalk. Ligand-Receptor interaction modeling in KPC-MUC16KO tumors (n=2) shown using a H. Heatmap depicting number of interactions between different cell types, I. Specific Ligand-Receptor pairs involved in macrophage-to-target cell crosstalk, J. Specific Ligand-Receptor pairs involved in source cell type-to-macrophage crosstalk.

Ligand-Receptor Interaction (LRI) analysis further highlighted distinct TME communication networks. In KPC tumors, the highest number of LRI occurred through fibroblasts populations, both intra-fibroblast interactions and from fibroblast to endothelial cells, macrophages, epithelial cells and proliferating immune cell interactions (Figure 6E). Macrophages showed the third-highest number of LRIs, particularly macrophage-macrophage and macrophage-fibroblast interactions (Figure 6E). Notably, a cis LRI between amyloid precursor protein (APP) and CD74 on macrophages was enriched in KPC tumors (Figure 6F), consistent with its reported role in promoting immunosuppression in testicular cancer and glioblastoma [47,48]. Additional LRIs directed toward the low-density lipoprotein receptor (LRP1), including C1QB-LRP1 and APOE-LRP1 interactions between macrophages and dendritic cells, have also been linked to immunosuppressive TMEs (Figure 6F) [49-51]. Conversely, multiple fibroblast-to-macrophage LRIs involving collagen and integrin-encoding genes suggest a crucial role for fibroblasts in driving the aggressive and immunosuppressive TME observed in KPC tumors (Figure 6G) [52].

In contrast, the KPC-MUC16KO tumors displayed a distinct interaction landscape, with many LRIs directed toward proliferating immune cells (Figure 6H). KPC-MUC16KO fibroblasts exhibited ~40 LRIs with proliferating immune cells, a pattern unique to the MUC16KO condition, as fibroblasts in KPC tumors predominantly interacted with other fibroblasts (Figure 6E). Macrophage sourced “ligands” were also markedly distinct in the less aggressive KPC-MUC16KO tumors, with high representation of MHC class II-associated HLA “ligands” pairing with CD4 and LAG3 on proliferating immune cells (Figure 6I), indicative of both immune-stimulating and LAG3-mediated immune inhibitory signaling. Both MUC16KO tumors showed increased MHC class I expression (elevated H2-K1) (Supplemental Figure 4D) and increased C3 expression indicative of enhanced complement activation (Supplemental Figure 4E), consistent with a more immune-active environment. Further, KPC-MUC16KO tumors exhibited S100A9-ITGB2 LRI between neutrophils and macrophages, a known driver of neutrophil recruitment and pro-inflammatory signaling (Figure 6I) [53].

Overall, immune-activating LRIs such as MHC class II-to-CD4 (HLA-DR, DQ, DM) and HLA-A-to-CD3D were enriched in KPC-MUC16KO tumors, immune-suppressive LRIs involving LAG3 were also found [54]. These findings suggest that although MUC16KO tumors initially exhibit a more immunologically active TME, they may eventually develop compensatory immunosuppressive features. This supports strategies combining MUC16-targeted interventions with immune-stimulating therapies such as CD40 agonists PDAC.

Discussion

The development of strategies to target pancreatic cancer has remained a huge focus in cancer biology, yet progress has been limited due to the highly complex tumor microenvironment (TME), which renders many therapeutic approaches ineffective. Immune checkpoint blockade (ICB) is a prominent example: whereas melanomas with high tumor mutational burden (TMB) generate abundant neoantigens and respond well to anti-PD(L)-1 and anti-CTLA-4 therapies [55-57], PDAC generally exhibits low TMB and an “immune desert” phenotype, characterized by profound immunosuppression and poor response to ICB [58-60].

Oncogenic KRAS itself drives a “fibroinflammatory” niche that sustains PDAC progression [61]. Recent work targeting mutant KRAS (G12D) using the inhibitor MRTX1133 demonstrated tumor regression in an immune-dependent manner, accompanied by remodeling of the TME, including changes in cancer-associated fibroblast (CAF) and macrophage states, with a slight increase in anti-tumor antigen-presenting macrophages following KRAS G12D inhibition [62]. These findings underscore the critical role of the immune TME in supporting PDAC. Additionally, direct pharmacologic inhibition of RAS has recently entered the clinic. Daraxonrasib, a RAS-ON inhibitor demonstrates huge promise for patients with previously treated metastatic PDAC with the overall survival being 13.2 months in the overall population compared to 6.7 months on chemotherapy (hazard ratio 0.40) [5]. Preclinical studies show that Daraxonrasib also facilitates infiltration of exhausted T cells and Tregs, and can prime the TME to anti-CTLA4 ICB [63]. Combining KRAS inhibitors like Daraxonrasib with anti-MUC16 antibodies to target similar immunosuppression could potentially result an active immune TME and better tumor burden outcomes in PDAC.

Mutant KRASG12D has also been shown to upregulate MUC16 [8], and depletion of MUC16 in KRAS-driven PDAC models reduces tumor growth and metastasis by altering the TME [9,64]. In our study, we report for the first time that MUC16 regulates macrophage-mediated immunosuppression in PDAC. Age-matched (4-month-old) KPC and KPC-MUC16KO mice displayed a clear difference in tumor features, with reduced stromal dysplasia in the latter group (Figure 1). The PDAC stroma comprising CAFs, immune cells, stellate cells, collagen, and other ECM components evolve alongside the tumor and plays a central role in promoting disease progression [7,65,66]. Myeloid cells, especially tumor-associated macrophages form a major stromal component of the immunosuppressed TME [17,23,67]. Using GEMMs and orthotopic models, we show that loss of MUC16 drastically restructures the TME, particularly influencing macrophage populations. MUC16 promotes infiltration and maintenance of TAMs, and this immunosuppressive role of MUC16 is supported by both in vitro and in vivo evidence from our study. These findings are consistent with reports that link MUC16 to enhanced fibrosis in PDAC [64], in line with known macrophage contributions to PDAC-associated fibrosis [18,68].

Our results identify CCL2 and Serpin-E1 as two cytokines regulated by MUC16 that contribute to macrophage infiltration and polarization in PDAC [31,33]. Although neutralizing these cytokines in tumor-conditioned media reduced macrophage migration in vitro, dual blockade did not fully recapitulate the reduced macrophage recruitment seen with MUC16KO cells. This suggests that additional MUC16-dependent secreted factors, yet to be identified, also promote macrophage trafficking toward MUC16-expressing PDAC cells. Thus, targeting MUC16 itself, rather than individual cytokines, may provide a more effective strategy in MUC16-high PDAC. Additionally, our data identify CCL2 and Serpin-E1 as downstream mediators of MUC16, with the former via AKT/NF-kB activation, but do not establish the mechanistic link between these cytokine activations. MUC16 has been shown to activate AKT signaling via focal adhesion kinase activation [69,70], we have also shown that MUC16 interacts with ErbB2 receptors (through proximity ligation assays) in previous studies [9]. Whether the intracellular tail or the extracellular domain of MUC16 mediates such FAK and ErbB family interactions is unknown. Another possibility is that the large glycosylated ectodomain of MUC16 acts on immune cells directly through Siglec-7/9 receptors, as previously indicated [16]. Distinguishing how these possibilities lead to immunosuppressive cytokine production in MUC16-expressing cells will require targeted experiments to establish a direct and mechanistic causal relationship between MUC16 and immune-modulatory cytokines.

We further show that MUC16-expressing PDAC cells strongly polarize BMDMs toward an immunosuppressive TAM phenotype, characterized by increased CD206, Arg1, and elevated expression of IL-10, CXCL13, CD274, and IL-1β. This mirrors observations from in vivo tumor models and highlights a direct role for MUC16 in shaping the immune landscape. Similar immune-modulatory functions have been described for glycosylated MUC1, reinforcing oncogenic mucins as relevant therapeutic targets in PDAC [71].

Macrophage depletion using clodronate liposomes significantly lowered tumor burden in KPC (MUC16-competent) mice but had minimal impact on KPC-MUC16KO tumors, underscoring the dependence of MUC16-expressing tumors on TAMs. Interestingly, clodronate treatment depleted F4/80+ macrophages in the spleen, but not within tumors, suggesting that systemic modulation without intratumoral macrophage depletion can influence tumor-associated immune populations. Recent work reporting tolerogenic dendritic cells in the spleens of PDAC patients supports the notion that the spleen may serve as an important immunoregulatory site in this disease [72]. Given its role as a secondary lymphoid organ, PDAC-induced alterations in splenic immune populations could have both systemic and local effects that promote disease progression. Although macrophage depletion reduced tumor burden, it did not alter intratumoral T cell populations. Instead, we observed an increase in active regulatory T cells in the spleen, which could lead to long-term resistance to macrophage depletion and increase the risk of disease recurrence (Figure 5). Consistent with our findings, another study demonstrated that depletion of CSF-1R+ macrophages fails to activate T cells and that reprogramming myeloid cells using CD40 agonist is more effective in PDAC [73]. Because macrophages function as professional antigen-presenting cells (APCs), CD40-mediated reprogramming may restore their antigen-presenting capacity and enhance durable anti-tumor immune responses. An important future direction of this work is to evaluate combined MUC16 inhibition and CD40 agonism.

A limitation of our macrophage depletion model is the absence of intratumoral macrophage depletion. This may reflect limited penetration of clodronate liposomes into the highly dysplastic, poorly vascularized PDAC tissue particularly as tumor interstitial pressure rises with disease progression [74]. It may also be due to inadequate dosing or the presence of macrophage subsets that do not efficiently phagocytose liposomal clodronate. Some studies have combined clodronate liposomes with CSF-1 neutralizing antibodies for more comprehensive macrophage depletion [18]; comparing such approaches with CD40 agonism could further clarify the relative contributions of macrophage depletion versus reprogramming in restoring anti-tumor immunity. We performed spatial transcriptomic analyses in an orthotopic model, which allowed us to assess tumor-cell-restricted loss of MUC16 in a MUC16-intact host. This avoided confounders from a whole-body Muc16-null model affecting the analyses, but this approach has limitations. Orthotopic tumors are established from implanted cells rather than arising through stepwise progression from PanIN, and implantation produces an acute wound response that is absent in the autochthonous models. The short tumor growth period does not capture the native TME that develops over months of progression in a genetically engineered model and may therefore not reflect the full extent of immune remodeling observed. The macrophage programs described here should therefore be interpreted as those arising in an established tumor rather than across the full course of tumor evolution. We note that the macrophage phenotypes identified by spatial transcriptomics are consistent with the immune profiling performed in the GEMM models (Figure 1), which supports the relevance of these findings. However, future studies using autochthonous mouse models are needed.

A major outcome of this study is that at a given model age, MUC16-bearing tumors in PDAC progress more rapidly than MUC16KO models, and our macrophage depletion studies (Figure 4) indicate that immunosuppressive macrophages contribute to this in the former group. Future studies will use late-stage MUC16KO models to evaluate how the MUC16-lacking PDAC TME is shaped and whether the immune profiles described herein persist or change despite slower disease progression in MUC16KO models.

In conclusion, our findings demonstrate that MUC16 promotes an immunosuppressive tumor microenvironment in pancreatic cancer and enhances tumor-associated macrophage (TAM)-mediated tumor progression. These results identify MUC16 as a potential therapeutic target to overcome immune suppression and improve the efficacy of immunotherapies, including immune checkpoint inhibitors, in PDAC. Furthermore, combining MUC16-targeted therapies with immune-activating strategies, such as CD40 agonists, may provide a promising approach to enhance and sustain anti-tumor immune responses.

Methods

Cell Lines and Culture

Murine PDAC cell lines (KPC and KPC-MUC16KO) were generated from tumors in 4-month-old mice in the C57BL/6 background. Briefly, the tumor was excised and chopped with a blade, followed by collagenase IV digestion for 20 mins at 37°C in a shaker. Cells were passaged in Dulbecco's Modified Eagle Medium (DMEM) or Roswell Park Memorial Institute 1640 Medium (RPMI) with 10% fetal bovine serum (FBS), 1% antibiotic cocktail (Penicillin-Streptomycin) for more than 8 passages to eliminate non-cancer cells, before expanding and using in experiments. No morphological changes were observed in these cells up to 20 passages.

Human isogenic PDAC cell lines T3M4 and Capan-1 were grown in complete media described above. MUC16KO lines were generated using CRISPR-Cas9 using a MUC16 knockout plasmid (Santa Cruz, #sc-403050), and single-cell clones were selected and expanded as described previously [9].

Genetically Engineered Mouse Models of PDAC

All animal breeding experiments were conducted in the University of Nebraska Medical Center (UNMC) animal house core facility under standard housing conditions and were approved by the Institutional Animal Care and Use Committees (IACUC). In all animal studies described herein, both male and female animals were used. Sex was not considered as a biological variable. MUC16-knockout animals in the C57BL/6 background were obtained from Dr. Richard R Behringer at MD Anderson Cancer Center [26]. Experimental KPC-MUC16KO mice were generated by breeding KrasLSLG12D/+; p53R172H/+; Pdx-CreTg/+ (KPC) animals with MUC16KO animals. Genotyping was done using the following primers:

KRAS Y116 5’-TCCGAATTCAGTGACTACAGATG-3’;

KRAS Y117 5’-CTAGCCACCATGGCTTGAGT-3’;

KRAS Y118 5’-ATGTCTTTCCCCAGCACAGT-3’;

TP53 T035 5’-CTTGGAGACATAGCCACACTG -3’;

TP53 T036 5’-AGCTAGCCACCATGGCTTGAGTAAGTCTGCA -3’;

TP53 T037 5’-TTACACATCCAGCCTCTGTGG -3’;

Pdx-Cre Fwd-5: 5'-CTGGACTACATCTTGAGTTGC-3';

Pdx-Cre Rev-5: 5'-GGTGTACGGTCAGTAAATTTG-3';

CA125 F 5'-CAGCATTTCCTATCCAATCACTAACCAG-3';

CA125 R 5'-CTAGATTGTATCTGAGCTGTGGTC C-3;

CA125 LacZ R 5'-GAAACCAGGCAAAGCGCCATTC-3'

Orthotopic Mouse Models of PDAC

6-to-8-week-old C57BL/6 mice were allowed to acclimate at the UNMC animal house core facility under standard housing conditions according to protocols approved by the Institutional Animal Care and Use Committees (IACUC). KPC (n=6) or KPC-MUC16KO (n=9) cells (7500/30 μL PBS) were injected in the body of the pancreas as described previously [75] and animals were euthanized 24 days post orthotopic implantation. Upon euthanasia, tumors were isolated and tumor weight and volume were measured.

In a separate survival study using the orthotopic model, KPC (n=8) and KPC-MUC16KO (n=11) tumor-bearing C57BL/6 mice were kept under observation until humane endpoint was reached or animals died of disease, and median survival was calculated using the Kaplan-Meier analysis and significance was determined using the log rank test.

Macrophage Depletion using Clodronate Liposomes

6-to-8-week-old C57BL/6 mice were randomized to receive intravenous tail vein clodronate liposome or neutral liposome injections (Tribioscience, Sunnyvale, CA, USA) (dose 1, day −3) at 200 μL per 20-25 g body weight animal per manufacturer’s guidelines. Animals within these two groups were randomized again to be orthotopically implanted with KPC or KPC-MUC16KO cells as described above (day 0). Animals were administered with clodronate or control liposomes (i.v., tail vein, 150 μL per 20-25 g body weight animal) for five more doses on days 4, 8, 12, 16 and 20 post orthotopic implantation for sustained macrophage depletion. Animal body weight was measured every 2 days during the study. All animals were euthanized on day 21 post implantation and tumor weight and volume were measured. The spleens and tumors from all groups were isolated and processed for flow cytometry profiling or histology. H&E staining was done by the UNMC Tissue Science Facility.

Immunohistochemistry/Immunofluorescence

Formalin-fixed paraffin-embedded (FFPE) tissues were made by first storing isolated tumor samples in formalin for 24 hours, followed by transfer to 70% ethanol and embedding in paraffin. Unstained tissue slides were generated by the Tissue Science Facility at UNMC. Immunohistochemistry (IHC) was performed as previously described [9]. Briefly, slides were de-paraffinized and rehydrated with xylene, alcohol series (100% to 80%) and water, followed by antigen retrieval in citrate buffer (pH 6.0) heated to about 95°C in a cooker. Quenching with hydrogen peroxide and blocking with universal blocker (Thermo Fisher Scientific) was done next and primary antibodies were added to the slides and incubated overnight at 4°C. After washing with TBS, slides were incubated with HRP-secondary antibody for 1 hour at room temperature and washed with TBS. Staining was developed with 3,3′-diaminobenzidine tetrahydrochloride substrate (DAB, Vector Laboratories, Burlingame, CA, USA) and followed with a hematoxylin counterstain. Finally, slides were dehydrated with reverse alcohol series and xylene and mounted in mounting media and coverslip. Staining was analyzed by a pathologist and the histoscore was calculated as previously described [9]. For immunofluorescence, rehydrated slides were blocked with universal blocker as mentioned above and incubated overnight at 4°C with desired concentration of primary antibody. Next day slides were washed with TBS and incubated with secondary antibody for 1 hr at room temperature. After the secondary antibody and washing steps, slides were mounted in DAPI-containing mounting media (Invitrogen, USA).

RNA Sequencing of Cell Lines

KPC and KPC-MUC16KO cells were plated, and RNA was isolated at 80% confluency using the RNeasy Protect Mini Kit (Qiagen, Hilden, Germany) per manufacturer’s guidelines and RNA sequencing was conducted by Novogene (USA). Differentially expressed gene data was analyzed using the Ingenuity Pathway Analysis (IPA) software version 01-21-03 (Qiagen Inc, Hilden, Germany) [76]. The graphical summary was used for predicted activation and inhibition networks within the differentially expressed genes.

Cytokine Array

Tumor-conditioned media was generated from T3M4, and T3M4-MUC16KO cells and human cytokine profiling was conducted using the Proteome ProfilerTM Array (ARY005B, R&D Systems, MN, USA) per manufacturer’s protocol. Signal detection on the dot blot was done using the enhanced chemiluminescent kit (Bio-Rad) and signal intensity was determined using the Protein Array Analyzer plugin in ImageJ. Background values were subtracted, and fold change was calculated for cytokines expressed in T3M4 and T3M4-MUC16KO cell-derived conditioned media as a percent of positive control spots provided on the dot blot.

ELISA

Tumor-conditioned media was generated from T3M4, T3M4-MUC16KO, Capan-1 and Capan-1 MUC16KO cells and used to measure CCL2 secretion through a human CCL2 ELISA kit (Biolegend # 438807) according to manufacturer’s instructions. CCL2 standards provided were used along with conditioned media, and absorbance was measured at 450 nm using a SpectraMax M5e Microplate Reader (Molecular Devices). The standard curve was used to measure CCL2 levels in the tumor-conditioned media.

Western Blotting

Cell line lysates were collected when cells were at 75-80% confluency using a cell scraper and lysed in RIPA Buffer (Thermo Fisher Scientific) supplemented with protease inhibitor cocktail (Roche #11836170001) and run on a 4-20% SDS-PAGE (Bio-Rad #4561094) before transferring to a PVDF membrane (Millipore, USA). The membrane was blocked in 5% milk containing TBST and probed for proteins, using primary antibodies, overnight at 4°C on a shaker. Following TBST wash (three times, 6 minutes on shaker) after which the membrane was incubated with a HRP-conjugated secondary antibody followed by signal detection using the enhanced chemiluminescent kit (Bio-Rad).

Immunoblotting for MUC16

SDS-agarose gel electrophoresis was conducted to detect MUC16 as previously described [9], due its heavily glycosylated native state that yield a bulky protein difficult to resolve on SDS-PAGE. Briefly, tumor cells were lysed using RIPA lysis buffer (Thermo Fisher Scientific, Waltham, MA, USA) constituted with protease inhibitor cocktail (Roche) as described above. After protein quantification using the BCA kit (Thermo Fisher Scientific), 100 μg protein is loaded per lane and resolved on a 1.5% agarose gel followed by an overnight transfer process using capillary action onto a PVDF membrane (Millipore, USA) for 16 to 20 hours. The membranes are blocked for 1 hour in 5% milk prepared in TBST. Murine AR9.6 (anti-MUC16) antibody (1:500 dilution) (Quest PharmaTech, Canada) was used to probe the membrane overnight, followed by probing with an anti-mouse HRP-conjugated secondary antibody (1:1000) (Thermo Fisher Scientific). Blots were visualized using chemiluminescent kit (Bio-Rad)

Generation of BMDMs in vitro

Normal (non-tumor-bearing) C57BL/6 mice at 8-10-weeks-old were euthanized and the bones collected, and bone marrow-derived macrophages (BMDMs) generated as described previously [77]. The bone marrow was flushed out using a syringe and RBC lysis buffer was used to lyse red blood cells, followed by monocyte culture in macrophage growth medium: RPMI 1640 containing 1% antibiotics, 1% HEPES, 1% L-glutamine, 0.1% 50 mM beta-mercaptoethanol, 10% FBS, 10% sL929 supernatant for 5 days with media replenishment on day 3. Day 5 BMDMs were used for experiments described within the results.

RT-PCR

Cells were plated, and RNA was isolated at 80% confluency using the RNeasy Protect Mini Kit (Qiagen, Hilden, Germany) per manufacturer’s guidelines. 1 μg RNA/tube was converted to cDNA using the Verso cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA). RT-PCR was conducted using SYBR Green (Applied Bioscience, USA) and gene specific primers on the CFX96 Real-Time PCR System (Bio-Rad). Ct values were first normalized to a housekeeping gene control, and fold change was calculated using the ΔΔCt method.

Migration Assay using Transwell Chambers

MUC16WT or MUC16KO PDAC cells (40,000 cells) were seeded in the bottom chamber of a Transwell migration plate (Corning) and allowed to adhere overnight at 37°C, 5% CO2, or tumor-conditioned media was added to the bottom chamber. 8000 macrophages (BMDMs) were seeded in the upper chamber and allowed to migrate towards the cells or conditioned media in the lower chamber through 8-micron pores for 24 hours at 37°C, 5% CO2. Migrated cells were fixed and stained using the Hema3 staining kit and images were captured and migrated cells per field were counted. CCL2 and Serpin-E1 neutralization antibodies were used in the bottom chamber containing KPC (MUC16-expressing) cell-derived tumor-conditioned media and were used at 0.3 μg/mL.

Multiplex Cytokine Assay

Serum samples from mice (n=4/group) from the clodronate liposome study: KPC + control, KPC + Clodronate liposome, KPC-MUC16KO + control, KPC-MUC16KO + Clodronate liposomes and normal, non-tumor bearing 10-week-old C57BL/6 mice were collected. Muliplex cytokine/chemokine profiling was conducted using the MILLIPLEX® Mouse Cytokine/Chemokine Magnetic Bead Panel (Millipore Sigma, #MCYTMAG-70K-PX32) per manufacturer’s protocol. Data was extrapolated from a standard curve run with the test samples. The data were log-transformed to make the data more normally distributed and compared using ANOVA among the five groups. The post hoc comparison was conducted with BH method to control the false discovery rate for multiple comparisons. Heatmap plot was created for all five groups on all cytokines with the fold change between each group and the overall mean.

Tissue Dissociation: Spleens and Pancreas Tumors

Myeloid depleted tissues obtained from orthotopic tumor study using clodronate or neutral liposomes were processed as follows. Spleens were mushed using the back flat tip of a 10-mL sterile syringe and cells were filtered through a 70-micron filter to remove debris. RBC lysis was conducted, and the immune cells were counted and then stained for macrophages and T cell populations. Pancreas tumors were chopped on ice in a petri dish containing media, and collagenase digestion was done as described above. The isolated cells were filtered through a 70-micron filter as above and the cell fraction was counted and stained for macrophage and T cells.

Flow Cytometry

The isolated splenocytes and tumor cell fractions were stained for live cells using the Live/Dead Fixable Blue Dead Cell Stain Kit (Thermo Fisher Scientific; Cat.-No.: L23105). Macrophages were stained as follows: F4/80 (total macrophages), CD86 and iNOS (M1-like macrophages), CD206 (M2-like macrophages). T cells were stained as follows: CD3 (Total T cells), CD4 (T helper cells), CD8 (Cytotoxic T cells), FOXP3 and CD25 (regulatory T cells). Refer to table on antibodies.

For in vitro studies using BMDMs, staining panel was as follows: F4/80 (total macrophages), CD86 and iNOS (M1-like macrophages), CD206 and Arg-1 (M2-like macrophages). All flow cytometry samples were run on the LSR II Green instrument (BD Bioscience) at the UNMC Flow Cytometry Core Facility. Analysis was done using FlowJo software (version 10.8.1, BD Bioscience). Frequency of parent graphs are plotted using GraphPad Prism version 10.0.1 (GraphPad Software Inc).

Spatial transcriptomic analysis (Visium HD)

FFPE blocks of orthotopic KPC and KPC-MUC16KO tumors (as described above) were used to create freshly sliced sections. Upon H&E staining and examination of appropriate tissue architecture and tumor features, samples (KPC and KPC-MUC16KO, n=2 each) were shipped to Genomics Core at NJH Colorado on ice. Data was analyzed as follows: Raw Data Processing, Quantification, Quality Control Analysis, and Clustering Analysis: Initial data processing was carried out via the 10x Genomics Cell Ranger (v3.1) using 10x Genomics Cloud Analysis. The "Visium HD Spatial Gene Expression" option for the "Library, Feature, or Image Type" parameter was set for each sample on the 10X cloud platform. The expression data quantified in the 8 μm window was considered for further downstream analysis. Quality control (QC) analysis was performed on four tissue samples using the standardized Seurat (V5.3.0) R package [78] pipeline optimized for Visium HD spatial transcriptomics that can be found at https://satijalab.org/seurat/articles/visiumhd_analysis_vignette (accessed on July 2nd, 2025) designed by the Satija Lab. To enhance the resolution and detection of rare or spatially restricted cell populations, we applied the standardized leverage score as the sketching method across all samples. QC metrics were assessed by generating violin and feature plots (representing counts) both before and after SCTransform normalization. Spatial gene expression maps were generated for Krt19 (positive control for all samples) and Muc16 (negative control for MUC16 knockout samples) to validate data integrity and assess spatial expression specificity. In addition, we included feature plots that visualize the expression patterns of distinct annotated cell types, accompanied by a histogram summarizing cell type representation across the dataset. Regions with <100 genes expressed were pruned from further processing. The top 3000 variable genes were considered for downstream analysis. The top 20 principal components were chosen for clustering and UMAP analysis based on the ElbowPlot visualization, and a resolution parameter of 0.4 was used to identify clusters with similar transcriptomic profiles in each data set.

Reference-Based Cell Type Annotation with SingleR

We performed automated cell type annotation using the SingleR (v1.12.1) [79], which assigns labels by comparing each cell’s transcriptome to reference profiles of known cell types. As a reference, we used the single-cell RNA-seq dataset from Hosein et al [80]. This reference captures diverse epithelial, stromal, and immune populations across normal pancreas, early-stage, and late-stage pancreatic adenocarcinoma (PDA) in mice.The Hosein dataset was processed using Seurat R package and integrated using CCA (IntegrateLayers(method = CCAIntegration)) across tissues, followed by dimensionality reduction (PCA, UMAP) and clustering. Gene expression profiles from this integrated object were used to build the reference for annotation of our in-house visiumHD datasets. For each query in-house visiumHD dataset, we performed downsampling (max 5,000 cells) to reduce computational load before reference-based cell type annotation using SingleR. To propagate the annotations from the downsampled query back to the full dataset, we performed label transfer using Seurat’s FindTransferAnchors and TransferData functions with the reference reduction set to "pca" and dims = 1:10. Predicted cell type annotations were added back to the full Seurat object using AddMetaData () utility.

Visualization and Cell Population Analysis

UMAP plots labeled by predicted cell types were generated using scCustomize(v3.0.1) [81], and proportion bar plots were constructed using Proportion_Plot ( ) with cell type ordering based on frequency. Summary tables of cell type distributions were plotted using “gridExtra” and exported as PDF. Relative frequencies were calculated and compared across samples using base R and visualized with ggplot2 (v3.5.2) [82]. All analyses were conducted in R [83] version 4.4.3 (2025-02-28) on macOS Sequoia 15.4.

Cell-Cell Communication Analysis

Cell-cell communications were inferred using the LIANA (Ligand–Receptor Interactions Analysis) framework in R (https://pubmed.ncbi.nlm.nih.gov/39223377/). To ensure robust inference, we employed a consensus-based approach by aggregating results from several scoring functions, including CellPhoneDB, NATMI, and CytoTalk. Significance was determined through a permutation-based approach (n = 1,000), where p-values reflect the proportion of permutations yielding a random mean expression higher than the observed value. Interactions were filtered based on an aggregate rank threshold (≤ 0.01) and cellphonedb p-value (< 0.05) to prioritize high-confidence consensus pairs.

Statistical Analysis

For all data collected from in vitro and in vivo studies (GEMM and orthotopic models), unless otherwise specified, the results of the analyses are represented as mean ± standard deviation (SD), and the significance was determined by an ordinary one-way analysis of variance (ANOVA) with Tukey’s multiple comparison test. GraphPad Prism v10 (GraphPad Software Inc) was used to prepare representative graphs.

Supplementary Material

1

Supplementary Figure 1: In vitro studies with T3M4 cells. A. Dot blot and protein array analyzer layout in ImageJ for cytokine profiling of tumor-conditioned media from T3M4 and T3M4-MUC16KO cells; B. Migration of THP-1 derived macrophages towards control (media without cells), T3M4 and T3M4-MUC16KO cells. **** = p ≤ 0.0001.

2

Supplementary Figure 2: In vitro studies using BMDMs. A. Differentiation of monocytes isolated from the bone marrow of 8-10-week-old C57BL/6 mice (day 0) to macrophages (day 5) after seeding in macrophage differentiation media containing M-CSF derived from L929 cells. Flow cytometry shows BMDMs express F4/80; B. Flow cytometry quantification for live cells and F4/80+ macrophages in the tumor cell-macrophage coculture; C. Flow cytometry quantification for live cells and F4/80+ macrophages in the KPC and KPC-MUC16KO tumor conditioned media (CM) study.

3

Supplementary Figure 3: Clodronate liposomes have systemic effects. A. Heatmap depicting log2 fold change values for a panel of 32 cytokines from serum of mice from the following groups: KPC + control liposomes, KPC + clodronate liposomes, KPC-MUC16KO + control liposomes, KPC-MUC16KO + clodronate liposomes (n=4/group); B. Median body weight of animals from the above groups measured every 2 days.

4

Supplementary Figure 4: Spatial transcriptomics shows comprehensive TME landscape in KPC and KPC-MUC16KO tumors. A. Heatmap depicting annotated gene clusters identifying cell types in orthotopic KPC (n=2) and KPC-MUC16KO tumors. B. Spatial distribution of cell types including epithelial cells, dendritic cells, fibroblasts, endothelial cells, macrophages, proliferating immune cells and B cells in a KPC (sample 2097) and a KPC-MUC16KO (sample 4336) tumor. Note: sample 4336 achieved incomplete spatial mapping post quality control. C. Arginase-1 spatial gene expression in a KPC (sample 2097) and a KPC-MUC16KO (sample 4336) tumor. D. H2-K1 spatial gene expression in KPC (samples 4690, 2097) and KPC-MUC16KO (samples 4342, 4336) tumors. E. C3 spatial gene expression in KPC (samples 4690, 2097) and KPC-MUC16KO (samples 4342, 4336) tumors.

Table 1: Reagents used.

Product name Manufacturer Catalog no. Species
Reactivity
Purpose
Compensation beads Invitrogen 01-3333-41 x Flow cytometry
Fixative solution BD 554714 x Flow cytometry
Permeabilization solution x Flow cytometry
F4/80 PE/Cy7 Biolegend 157308 Mu Flow cytometry
CD206 AF647 Biolegend 141712 Mu Flow cytometry
Arginase-1 PE Biolegend 165804 Mu Flow cytometry
CD86 BV785 Biolegend 105043 Mu Flow cytometry
iNOS ef450 eBioscience 48-5920-82 Mu Flow cytometry
Live/dead fix blue ThermoFisher L23105 x Flow cytometry
CD8a PE Biolegend 100708 Mu Flow cytometry
CD4 BV650 Biolegend 100469 Mu Flow cytometry
CD3 AF488 Biolegend 100210 Mu Flow cytometry
TruStain FcX™ (anti-mouse CD16/32) Biolegend 101320 Mu Flow cytometry
p-AKT (S473) Cell signaling technology 4060 Hu, Mu Western blotting
AKT Cell signaling technology 9272 Hu, Mu Western blotting
p-IKKα/β (Ser176/180) Cell signaling technology 2697 Hu, Mu Western blotting
IKKα Cell signaling technology 61294 Hu, Mu Western blotting
Serpin-E1 Novus Biologicals NBP1-19773 Hu, Mu Western blotting, Neutralization, IHC
CCL2 Novus Biologicals NBP1-07035 Hu, Mu Western blotting, IF
GAPDH Cell signaling technology 2275 Hu, Mu Western blotting
CCL2 Clone # 123616 R&D Systems MAB479 Mu Neutralization
Murine AR9.6 (anti-MUC16) Quest PharmaTech n/a Hu. Mu Western blotting, IF

Mu = mouse, Hu = human

Highlights:

  • MUC16 drives oncogenic signaling and macrophage-mediated immunosuppression in PDAC

  • MUC16 activates CCL2 and Serpin-E1 signaling to recruit and polarize macrophages

  • Loss of MUC16 drastically reduces tumor burden and immunosuppressive macrophages

  • Targeting MUC16 combined with TME macrophages presents a novel therapeutic strategy

Acknowledgements:

We thank Dr. Trey Farmer at the Genomics Core, National Jewish Health in Colorado for his support and assistance with the Visium HD spatial transcriptomics study.

Funding:

This work was supported in part by the National Institutes of Health/National Cancer Institute (NIH/NCI) grant CA288372 (to PR) and by the American Cancer Society Research Scholar Grant RSG-22-100-01-1278 CDP (to PR).

Footnotes

Consent for publication:

All authors agree to the publication of this article.

Generative AI:

There was no use of generative-AI or AI-assisted technologies in the preparation or design of this work.

Animal subject

This study was conducted in accordance with the following guidelines for animal welfare and/or reporting: IACUC.

This study was approved by the IACUC.

(Approval No. 23-024-04)

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Data availability statement:

The datasets generated in this study are available to access at the Gene Expression Omnibus (GEO). RNA-sequencing of mouse PDAC cell lines (KPC and KPC-MUC16KO) can be found at GEO under accession number GSE324652. Datasets from the spatial transcriptomic sequencing through the VisiumHD platform used on orthotopic KPC and KPC-MUC16KO tissues can be found under accession number GSE335927.

References:

  • [1].Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nature Reviews Disease Primers 2016 2:1 2016;2:1–22. 10.1038/nrdp.2016.22. [DOI] [PubMed] [Google Scholar]
  • [2].Pancreatic Cancer — Cancer Stat Facts n.d. https://seer.cancer.gov/statfacts/html/pancreas.html (accessed September 26, 2022).
  • [3].Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. New England Journal of Medicine 2011;364:1817–25. 10.1056/NEJMOA1011923/SUPPL_FILE/NEJMOA1011923_DISCLOSURES.PDF. [DOI] [PubMed] [Google Scholar]
  • [4].Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardière C, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. The Lancet 2023;402:1272–81. 10.1016/S0140-6736(23)01366-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5].O’Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, et al. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. New England Journal of Medicine 2026;395:325–62. 10.1056/NEJMOA2605555;WGROUP:STRING:MMS. [DOI] [PubMed] [Google Scholar]
  • [6].FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma ∣ FDA; n.d. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma (accessed September 6, 2026). [Google Scholar]
  • [7].Hingorani SR. Epithelial and stromal co-evolution and complicity in pancreatic cancer. Nature Reviews Cancer 2022 23:2 2022;23:57–77. 10.1038/s41568-022-00530-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [8].Liang C, Qin Y, Zhang B, Ji S, Shi S, Xu W, et al. Oncogenic KRAS targets MUC16/CA125 in pancreatic ductal adenocarcinoma. Molecular Cancer Research 2017;15:201–12. 10.1158/1541-7786.MCR-16-0296/288701/P/ONCOGENIC-KRAS-TARGETS-MUC16-CA125-IN-PANCREATIC. [DOI] [PubMed] [Google Scholar]
  • [9].Thomas D, Sagar S, Liu X, Lee HR, Grunkemeyer JA, Grandgenett PM, et al. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer. Molecular Therapy 2021;29:1557–71. 10.1016/J.YMTHE.2020.12.029/ATTACHMENT/632DD631-FCE4-4079-AC9E-940B42278BB0/MMC1.PDF. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10].Karamitopoulou E. Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features. British Journal of Cancer 2019 121:1 2019;121:5–14. 10.1038/s41416-019-0479-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [11].Yang J, Zhang Q, Wang J, Lou Y, Hong Z, Wei S, et al. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy. EBioMedicine 2022;78. 10.1016/J.EBIOM.2022.103958/ATTACHMENT/63F17E9B-A699-44E7-B79A-C26B0A3D9DD9/MMC1.DOCX. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12].Karam AK, Karlan BY. Ovarian cancer: the duplicity of CA125 measurement. Nature Reviews Clinical Oncology 2010 7:6 2010;7:335–9. 10.1038/nrclinonc.2010.44. [DOI] [PubMed] [Google Scholar]
  • [13].Belisle JA, Gubbels JAA, Raphael CA, Migneault M, Rancourt C, Connor JP, et al. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology 2007;122:418–29. 10.1111/j.1365-2567.2007.02660.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [14].Felder M, Kapur A, Rakhmilevich AL, Qu X, Sondel PM, Gillies SD, et al. MUC16 suppresses human and murine innate immune responses. Gynecol Oncol 2019;152:618–28. 10.1016/j.ygyno.2018.12.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [15].Gubbels JAA, Felder M, Horibata S, Belisle JA, Kapur A, Holden H, et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer 2010;9. 10.1186/1476-4598-9-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [16].Belisle JA, Horibata S, Jennifer GAA, Petrie S, Kapur A, André S, et al. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer 2010;9:1–14. 10.1186/1476-4598-9-118/FIGURES/8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [17].Kaneda MM, Cappello P, Nguyen AV, Ralainirina N, Hardamon CR, Foubert P, et al. Macrophage PI3Kγ drives pancreatic ductal adenocarcinoma progression. Cancer Discov 2016;6:870–85. 10.1158/2159-8290.CD-15-1346/42496/AM/MACROPHAGE-PI3K-DRIVES-PANCREATIC-DUCTAL. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [18].Zhu Y, Herndon JM, Sojka DK, Kim KW, Knolhoff BL, Zuo C, et al. Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. Immunity 2017;47:323–338.e6. 10.1016/J.IMMUNI.2017.07.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [19].Zuo C, Baer JM, Knolhoff BL, Belle JI, Liu X, Hogg GD, et al. Macrophage proliferation machinery leads to PDAC progression, but susceptibility to innate immunotherapy. BioRxiv 2021:2021.11.08.467770. 10.1101/2021.11.08.467770. [DOI] [Google Scholar]
  • [20].Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 2013;73:1128–41. 10.1158/0008-5472.CAN-12-2731/650746/AM/TARGETING-TUMOR-INFILTRATING-MACROPHAGES-DECREASES. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [21].Griesmann H, Drexel C, Milosevic N, Sipos B, Rosendahl J, Gress TM, et al. Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer. Gut 2017;66:1278–85. 10.1136/GUTJNL-2015-310049. [DOI] [PubMed] [Google Scholar]
  • [22].Liou GY, Döppler H, Necela B, Edenfield B, Zhang L, Dawson DW, et al. Mutant KRAS–induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions. Cancer Discov 2015;5:52–63. 10.1158/2159-8290.CD-14-0474/42491/AM/MUTANT-KRAS-INDUCED-EXPRESSION-OF-ICAM-1-IN. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [23].Liou GY, Döppler H, Necela B, Krishna M, Crawford HC, Raimondo M, et al. Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs. Journal of Cell Biology 2013;202:563–77. 10.1083/JCB.201301001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [24].Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437–50. 10.1016/S1535-6108(03)00309-X/ATTACHMENT/E4365F87-FD7D-4C83-B8BD-E8C99A4B7F21/MMC1.PDF. [DOI] [PubMed] [Google Scholar]
  • [25].Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7:469–83. 10.1016/J.CCR.2005.04.023/ATTACHMENT/5A08165E-7F4C-4E88-AA1D-384C993E274E/MMC1.PDF. [DOI] [PubMed] [Google Scholar]
  • [26].Cheon DJ, Wang Y, Deng JM, Lu Z, Xiao L, Chen CM, et al. CA125/MUC16 Is Dispensable for Mouse Development and Reproduction. PLoS One 2009;4:e4675. 10.1371/JOURNAL.PONE.0004675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [27].Kopp JL, von Figura G, Mayes E, Liu FF, Dubois CL, Morris JP, et al. Identification of Sox9-Dependent Acinar-to-Ductal Reprogramming as the Principal Mechanism for Initiation of Pancreatic Ductal Adenocarcinoma. Cancer Cell 2012;22:737–50. 10.1016/j.ccr.2012.10.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [28].Stanczak MA, Mantuano NR, Kirchhammer N, Sanin DE, Jacob F, Coelho R, et al. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Sci Transl Med 2022;14. 10.1126/SCITRANSLMED.ABJ1270/SUPPL_FILE/SCITRANSLMED.ABJ1270_MDAR_REPRODUCIBILITY_CHECKLIST.PDF. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [29].Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A, et al. A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res 2014;7:1–16. 10.1186/1757-2215-7-19/FIGURES/4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30].Mestas J, Hughes CCW. Of Mice and Not Men: Differences between Mouse and Human Immunology. The Journal of Immunology 2004;172:2731–8. 10.4049/JIMMUNOL.172.5.2731. [DOI] [PubMed] [Google Scholar]
  • [31].Kubala MH, Punj V, Placencio-Hickok VR, Fang H, Fernandez GE, Sposto R, et al. Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer. Cell Rep 2018;25:2177–2191.e7. 10.1016/j.celrep.2018.10.082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [32].Andoh A, Takaya H, Saotome T, Shimada M, Hata K, Araki Y, et al. Cytokine regulation of chemokine (IL-8, MCP-1, and RANTES) gene expression in human pancreatic periacinar myofibroblasts. Gastroenterology 2000;119:211–9. 10.1053/GAST.2000.8538. [DOI] [PubMed] [Google Scholar]
  • [33].Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, et al. Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: A role for targeting the CCL2/CCR2 axis. Clinical Cancer Research 2013;19:3404–15. 10.1158/1078-0432.CCR-13-0525/85628/AM/INFLAMMATORY-MONOCYTE-MOBILIZATION-DECREASES. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [34].Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011 475:7355 2011;475:222–5. 10.1038/nature10138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [35].Kalbasi A, Komar C, Tooker GM, Liu M, Lee JW, Gladney WL, et al. Tumor-derived CCL2 mediates resistance to radiotherapy in pancreatic ductal adenocarcinoma. Clinical Cancer Research 2017;23:137–48. 10.1158/1078-0432.CCR-16-0870/128825/AM/TUMOR-DERIVED-CCL2-MEDIATES-RESISTANCE-TO. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [36].Nakatsumi H, Matsumoto M, Nakayama KI. Noncanonical Pathway for Regulation of CCL2 Expression by an mTORC1-FOXK1 Axis Promotes Recruitment of Tumor-Associated Macrophages. Cell Rep 2017;21:2471–86. 10.1016/J.CELREP.2017.11.014. [DOI] [PubMed] [Google Scholar]
  • [37].Zhao Z, Sun H, Liu Y, Zhang Y, Wang X, Wang X, et al. PDPN+ cancer-associated fibroblasts enhance gastric cancer angiogenesis via AKT/NF-κB activation and the CCL2-ACKR1 axis. MedComm (Beijing) 2025;6:e70037. 10.1002/MCO2.70037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [38].Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994;174:83–93. 10.1016/0022-1759(94)90012-4. [DOI] [PubMed] [Google Scholar]
  • [39].Mechanism of Action - Liposoma research liposomes n.d. https://clodronateliposomes.com/about-clodronate-liposomes/mechanism-of-action/ (accessed April 30, 2025).
  • [40].Marro BS, Legrain S, Ware BC, Oldstone MBA. Macrophage IFN-I signaling promotes autoreactive T cell infiltration into islets in type 1 diabetes model. JCI Insight 2019;4. 10.1172/JCI.INSIGHT.125067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [41].Schiedner G, Hertel S, Johnston M, Dries V, van Rooijen N, Kochanek S. Selective depletion or blockade of kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors. Molecular Therapy 2003;7:35–43. 10.1016/S1525-0016(02)00017-5. [DOI] [PubMed] [Google Scholar]
  • [42].Fu C, Jin X, Ji K, Lan K, Mao X, Huang Z, et al. Macrophage-targeted Mms6 mRNA-lipid nanoparticles promote locomotor functional recovery after traumatic spinal cord injury in mice. Science Advances 2025;11. 10.1126/SCIADV.ADS2295/SUPPL_FILE/SCIADV.ADS2295_SM.PDF. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [43].Jiang Y, Wang Y, Chen G, Sun F, Wu Q, Huang Q, et al. Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer. Cell Metab 2024;36:1806–1822.e11. 10.1016/J.CMET.2024.05.013/ASSET/E3AC76CC-594D-4EE1-827D-1447F06DF725/MAIN.ASSETS/FX1.JPG. [DOI] [PubMed] [Google Scholar]
  • [44].Laidlaw BJ, Craft JE, Kaech SM. The multifaceted role of CD4+ T cells in CD8+ T cell memory. Nature Reviews Immunology 2016 16:2 2016;16:102–11. 10.1038/nri.2015.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [45].Peppelenbosch MP, DeSmedt M, Pynaert G, van Deventer SJH, Grooten J. Macrophages Present Pinocytosed Exogenous Antigen Via MHC Class I Whereas Antigen Ingested by Receptor-Mediated Endocytosis Is Presented Via MHC Class II. The Journal of Immunology 2000;165:1984–91. 10.4049/JIMMUNOL.165.4.1984. [DOI] [PubMed] [Google Scholar]
  • [46].Wang X, Li Y, Li Y, Wang X, Song H, Wang Y, et al. AMPK-dependent Parkin activation suppresses macrophage antigen presentation to promote tumor progression. Science Advances 2025;11:8402. 10.1126/SCIADV.ADN8402/SUPPL_FILE/SCIADV.ADN8402_DATA_S1_TO_S9.ZIP. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [47].Chen G, Wang W, Wei X, Chen Y, Peng L, Qu R, et al. Single-cell transcriptomic analysis reveals that the APP–CD74 axis promotes immunosuppression and progression of testicular tumors. Journal of Pathology 2024;264:250–69. 10.1002/PATH.6343;REQUESTEDJOURNAL:JOURNAL:10969896;ISSUE:ISSUE:DOI. [DOI] [PubMed] [Google Scholar]
  • [48].Ma C, Chen J, Ji J, Zheng Y, Liu Y, Wang J, et al. Therapeutic modulation of APP-CD74 axis can activate phagocytosis of TAMs in GBM. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2024;1870:167449. 10.1016/J.BBADIS.2024.167449. [DOI] [PubMed] [Google Scholar]
  • [49].Zhou JX, Taramelli R, Pedrini E, Knijnenburg T, Huang S. Extracting Intercellular Signaling Network of Cancer Tissues using Ligand-Receptor Expression Patterns from Whole-tumor and Single-cell Transcriptomes. Scientific Reports 2017 7:1 2017;7:8815-. 10.1038/s41598-017-09307-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [50].Zhang S, Peng W, Wang H, Xiang X, Ye L, Wei X, et al. C1q+ tumor-associated macrophages contribute to immunosuppression through fatty acid metabolic reprogramming in malignant pleural effusion. J Immunother Cancer 2023;11:e007441. 10.1136/JITC-2023-007441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [51].Kemp SB, Carpenter ES, Steele NG, Donahue KL, Nwosu ZC, Pacheco A, et al. Apolipoprotein E promotes immune suppression in pancreatic cancer through NF-κB-Mediated production of CXCL1. Cancer Res 2021;81:4305–18. 10.1158/0008-5472.CAN-20-3929/673699/AM/APOLIPOPROTEIN-E-PROMOTES-IMMUNE-SUPPRESSION-IN. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [52].Chen Y, Yang S, Tavormina J, Tampe D, Zeisberg M, Wang H, et al. Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Cancer Cell 2022;40:818–834.e9. 10.1016/j.ccell.2022.06.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [53].Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA. Proinflammatory Activities of S100: Proteins S100A8, S100A9, and S100A8/A9 Induce Neutrophil Chemotaxis and Adhesion. The Journal of Immunology 2003;170:3233–42. 10.4049/JIMMUNOL.170.6.3233. [DOI] [PubMed] [Google Scholar]
  • [54].Gulhati P, Schalck A, Jiang S, Shang X, Wu CJ, Hou P, et al. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nature Cancer 2022 4:1 2022;4:62–80. 10.1038/s43018-022-00500-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [55].Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Annals of Oncology 2019;30:582–8. 10.1093/ANNONC/MDZ011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [56].Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine 2017;377:1345–56. 10.1056/NEJMOA1709684/SUPPL_FILE/NEJMOA1709684_DISCLOSURES.PDF. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [57].Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduction and Targeted Therapy 2024 9:1 2024;9:1–65. 10.1038/s41392-024-01979-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [58].Bear AS, Vonderheide RH, O’Hara MH. Challenges and Opportunities for Pancreatic Cancer Immunotherapy. Cancer Cell 2020;38:788–802. 10.1016/J.CCELL.2020.08.004/ASSET/95EBD177-FF54-4174-9237-6F1162022AB8/MAIN.ASSETS/GR1.JPG. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [59].Chakrabarti S, Bucheit L, Starr JS, Innis-Shelton R, Shergill A, Dada H, et al. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer. J Immunother Cancer 2022;10:e004485. 10.1136/JITC-2021-004485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [60].Nasar N, Eikenboom E, Seier K, Gonen M, Wagner A, Jarnagin WR, et al. Survival of patients with microsatellite instability-high and Lynch syndrome-associated pancreatic ductal adenocarcinomas. Journal of Clinical Oncology 2024;42:640–640. 10.1200/JCO.2024.42.3_SUPPL.640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [61].Collins MA, Bednar F, Zhang Y, Brisset JC, Galbán S, Galbán CJ, et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 2012;122:639–53. 10.1172/JCI59227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [62].Kemp SB, Cheng N, Markosyan N, Sor R, Kim IK, Hallin J, et al. Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer. Cancer Discov 2023;13:298–311. 10.1158/2159-8290.CD-22-1066/711367/AM/EFFICACY-OF-A-SMALL-MOLECULE-INHIBITOR-OF-KRASG12D. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [63].Mahadevan KK, Maldonado AS, Li B, Bickert AA, Kacperczyk-Perdyan A, Kumbhar SV, et al. Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer. Nature Communications 2026 2026. 10.1038/S41467-026-75960-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [64].Lakshmanan I, Marimuthu S, Chaudhary S, Seshacharyulu P, Rachagani S, Muniyan S, et al. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma. Oncogene 2022 41:48 2022;41:5147–59. 10.1038/s41388-022-02493-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [65].Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nature Reviews Gastroenterology & Hepatology 2020 17:8 2020;17:487–505. 10.1038/s41575-020-0300-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [66].Bulle A, Lim KH. Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. Signal Transduction and Targeted Therapy 2020 5:1 2020;5:1–12. 10.1038/s41392-020-00341-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [67].Nielsen SR, Quaranta V, Linford A, Emeagi P, Rainer C, Santos A, et al. Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nature Cell Biology 2016 18:5 2016;18:549–60. 10.1038/ncb3340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [68].Xue J, Sharma V, Hsieh MH, Chawla A, Murali R, Pandol SJ, et al. Alternatively activated macrophages promote pancreatic fibrosis in chronic pancreatitis. Nature Communications 2015 6:1 2015;6:1–11. 10.1038/ncomms8158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [69].Rajesh C, Sagar S, Rathinavel AK, Chemparathy DT, Peng XL, Yeh JJ, et al. Truncated O-Glycan-Bearing MUC16 Enhances Pancreatic Cancer Cells Aggressiveness via α4β1 Integrin Complexes and FAK Signaling. Int J Mol Sci 2022;23:5459. 10.3390/IJMS23105459/S1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [70].Muniyan S, Haridas D, Chugh S, Rachagani S, Lakshmanan I, Gupta S, et al. MUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism. Genes Cancer 2016;7:110. 10.18632/GENESANDCANCER.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [71].Rao TD, Fernández-Tejada A, Axelrod A, Rosales N, Yan X, Thapi S, et al. Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth. ACS Chem Biol 2017;12:2085–96. 10.1021/ACSCHEMBIO.7B00305/SUPPL_FILE/CB7B00305_SI_001.PDF. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [72].Mundry CS, Triplett AA, Shah OS, Chaitankar V, McAndrews KL, Ly QP, et al. Single-cell RNA-sequencing of human spleens reveals an IDO-1+ tolerogenic dendritic cell subset in pancreatic cancer patients that is absent in normal individuals. Cancer Lett 2024;607:217321. 10.1016/J.CANLET.2024.217321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [73].Stromnes IM, Burrack AL, Hulbert A, Bonson P, Black C, Brockenbrough JS, et al. Differential effects of depleting versus programming tumor-associated macrophages on engineered T cells in pancreatic ductal adenocarcinoma. Cancer Immunol Res 2019;7:977–89. 10.1158/2326-6066.CIR-18-0448/470607/AM/DIFFERENTIAL-EFFECTS-OF-DEPLETING-VERSUS. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [74].Heldin CH, Rubin K, Pietras K, Östman A. High interstitial fluid pressure - An obstacle in cancer therapy. Nat Rev Cancer 2004;4:806–13. 10.1038/NRC1456;KWRD=BIOMEDICINE. [DOI] [PubMed] [Google Scholar]
  • [75].Haney SL, Varney ML, Chhonker YS, Shin S, Mehla K, Crawford AJ, et al. Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma. Oncogene 2019 38:26 2019;38:5308–20. 10.1038/s41388-019-0794-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [76].Krämer A, Green J, Pollard J, Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 2014;30:523–30. 10.1093/BIOINFORMATICS/BTT703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [77].Mendoza R, Banerjee I, Manna D, Reghupaty SC, Yetirajam R, Sarkar D. Mouse Bone Marrow Cell Isolation and Macrophage Differentiation. Methods in Molecular Biology 2022;2455:85–91. 10.1007/978-1-0716-2128-8_8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [78].Hao Y, Stuart T, Kowalski MH, Choudhary S, Hoffman P, Hartman A, et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nature Biotechnology 2023 42:2 2023;42:293–304. 10.1038/s41587-023-01767-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [79].Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nature Immunology 2019 20:2 2019;20:163–72. 10.1038/s41590-018-0276-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [80].Hosein AN, Huang H, Wang Z, Parmar K, Du W, Huang J, et al. Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution. JCI Insight 2019;4. 10.1172/JCI.INSIGHT.129212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [81].Marsh SE. scCustomize: Custom Visualizations & Functions for Streamlined Analyses of Single Cell Sequencing 2021. https://samuel-marsh.r-universe.dev/scCustomize (accessed November 30, 2025).
  • [82].Villanueva RAM, Chen ZJ. ggplot2: Elegant Graphics for Data Analysis (2nd ed.). vol. 17. Routledge; 2019. 10.1080/15366367.2019.1565254. [DOI] [Google Scholar]
  • [83].R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. - References - Scientific Research Publishing; 2025. https://www.r-project.org/ (accessed November 30, 2025). [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1

Supplementary Figure 1: In vitro studies with T3M4 cells. A. Dot blot and protein array analyzer layout in ImageJ for cytokine profiling of tumor-conditioned media from T3M4 and T3M4-MUC16KO cells; B. Migration of THP-1 derived macrophages towards control (media without cells), T3M4 and T3M4-MUC16KO cells. **** = p ≤ 0.0001.

2

Supplementary Figure 2: In vitro studies using BMDMs. A. Differentiation of monocytes isolated from the bone marrow of 8-10-week-old C57BL/6 mice (day 0) to macrophages (day 5) after seeding in macrophage differentiation media containing M-CSF derived from L929 cells. Flow cytometry shows BMDMs express F4/80; B. Flow cytometry quantification for live cells and F4/80+ macrophages in the tumor cell-macrophage coculture; C. Flow cytometry quantification for live cells and F4/80+ macrophages in the KPC and KPC-MUC16KO tumor conditioned media (CM) study.

3

Supplementary Figure 3: Clodronate liposomes have systemic effects. A. Heatmap depicting log2 fold change values for a panel of 32 cytokines from serum of mice from the following groups: KPC + control liposomes, KPC + clodronate liposomes, KPC-MUC16KO + control liposomes, KPC-MUC16KO + clodronate liposomes (n=4/group); B. Median body weight of animals from the above groups measured every 2 days.

4

Supplementary Figure 4: Spatial transcriptomics shows comprehensive TME landscape in KPC and KPC-MUC16KO tumors. A. Heatmap depicting annotated gene clusters identifying cell types in orthotopic KPC (n=2) and KPC-MUC16KO tumors. B. Spatial distribution of cell types including epithelial cells, dendritic cells, fibroblasts, endothelial cells, macrophages, proliferating immune cells and B cells in a KPC (sample 2097) and a KPC-MUC16KO (sample 4336) tumor. Note: sample 4336 achieved incomplete spatial mapping post quality control. C. Arginase-1 spatial gene expression in a KPC (sample 2097) and a KPC-MUC16KO (sample 4336) tumor. D. H2-K1 spatial gene expression in KPC (samples 4690, 2097) and KPC-MUC16KO (samples 4342, 4336) tumors. E. C3 spatial gene expression in KPC (samples 4690, 2097) and KPC-MUC16KO (samples 4342, 4336) tumors.

Data Availability Statement

The datasets generated in this study are available to access at the Gene Expression Omnibus (GEO). RNA-sequencing of mouse PDAC cell lines (KPC and KPC-MUC16KO) can be found at GEO under accession number GSE324652. Datasets from the spatial transcriptomic sequencing through the VisiumHD platform used on orthotopic KPC and KPC-MUC16KO tissues can be found under accession number GSE335927.

RESOURCES